[18F]AlF-NOTA-FAPI-04 PET/CT in Inflammation and Fibrosis in Renal Diseases

Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Feb 21, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 18F-FAPI PET/CT to see how well it can evaluate inflammation and fibrosis (scarring) in kidney diseases. The main goal is to find out if this method can provide an accurate and non-invasive way to assess these conditions compared to traditional methods. Participants will undergo this imaging test along with a kidney biopsy, which is a procedure where a small sample of kidney tissue is taken for examination.

To be eligible for the study, participants should have kidney conditions like nephritis (inflammation of the kidney) or fibrosis. However, there are certain exclusions, such as having uncontrolled high blood pressure, severe bleeding disorders, or other serious health issues. The trial is open to individuals aged between 3 and 92 years, regardless of gender. If you decide to participate, you can expect to have your kidney condition evaluated using this new imaging technique, which could help improve how kidney diseases are diagnosed and monitored in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The pitients of nephritis or fibrosis disease
• Exclusion Criteria:
• • Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg
• • Renal biopsy cannot be performed for severe exclotting disease
• • Complicated with chronic liver disease, myocardial infarction, stroke, and malignant tumor
• • Unable to cooperate with renal puncture biopsy due to language communication or other problems
• • Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception
• • Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
• • Alcohol allergy
• • Patients with significant decrease in urine volume due to disease
• • Refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved protocol
• • Other circumstances deemed inappropriate by the investigator for participation in the study.